IL-13, IL-17A, IL-17F

Class

multispecific (IL-13/IL-17A/IL-17F) antibody with albumin-binding domain for extended half-life

Pathway

combined Th2 (IL-13) and Th17 (IL-17A/F) inflammatory signaling

This mechanism targets three cytokines from two distinct arms of the immune system: interleukin-13 (IL-13), a driver of Th2-type (allergic) inflammation, and interleukin-17A and interleukin-17F (IL-17A/F), effector cytokines of Th17-type inflammation. IL-13 promotes barrier dysfunction, mucus overproduction, and IgE-mediated allergic responses, while IL-17A/F drive neutrophil recruitment, antimicrobial peptide production, and epithelial hyperproliferation. These pathways were long considered largely separate, even opposing, but many chronic inflammatory skin and airway diseases show overlapping Th2 and Th17 activity, so blocking only one axis can leave the other unchecked and limit clinical benefit. A single molecule engineered to neutralize all three cytokines is designed to address this mixed inflammatory biology more completely than a selective single-pathway agent. The antibody also incorporates an albumin-binding domain, which allows it to piggyback on the body's recycling of serum albumin to extend its circulating half-life, supporting less frequent dosing. This combined approach is broadly relevant to immune-mediated inflammatory diseases of the skin and airways where Th2 and Th17 signaling coexist, such as certain forms of dermatitis and psoriatic disease.